Engility has been selected as one of the prime contractors on the US Army’s $900m medical product research and development (MPRD) contract.
The indefinite-delivery, indefinite-quantity contract covers the provision of professional and technical services supporting MPRD for the army and other Department of Defense entities, and has a five-year base performance period, as well as five, one-year options.
Under the contract, Engility subsidiary, TASC, will provide technical / administrative services, meeting and informational products, clinical and non-clinical development, medical product manufacturing, as well as regulatory, training protocol and information technology.
Engility president and CEO Tony Smeraglinolo said: "Engility appreciates the opportunity to provide unique technical support and innovative thought on this vital medical product research and development program, which ensures the servicemen and women who defend our country have the best medical supplies and medical assistance available.
"The MPRD contract is a very meaningful award and is projected to be a vehicle that is used throughout DoD for medical product research and development and support."
The MPRD programme provides a mechanism for all aspects of medical product research and development and lifecycle support to maintain US troops.
Managed by the Army Medical Research and Materiel Command, the contract will streamline the process, in which military medical products move through the development process and progress through Food and Drug Administration clearance or approval before fielding the product or knowledge to the soldier.
Other contract awardees include Dynport Vaccine, Leidos, and Pharmaceutical Product Development.
